Over the coming years, accelerating progress against cancer will be associated with an increased number of patients who require life‑sustaining therapies for infectious or toxic chemotherapy‑related events. Major changes include increased number of cancer patients admitted to the ICU with full‑code status or for time‑limited trials, increased survival and quality of life in ICU survivors, changing prognostic factors, early ICU admission for optimal monitoring, and use of noninvasive diagnostic and therapeutic strategies.

Read More